Celcuity Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Brian F. Sullivan
- Full Time Employees
- 155
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2800 Campus Drive Minneapolis MN United States of America 55446
- IPO Date
- Sep 19, 2017
- CIK
- 0001603454
- Website
- celcuity.com
- Similar Companies
- Business
- Celcuity Inc. (Nasdaq: CELC) is a clinical-stage biopharmaceutical company developing targeted therapies for cancer patients using its proprietary CELsignia platform to identify those most likely to benefit from specific treatments. The platform analyzes live tumor cells to measure signaling pathway activity, enabling precision oncology by matching patients to therapies based on tumor biology rather than traditional biomarkers. Core offerings include the CELsignia test service, which provides diagnostic signaling profiles for breast, lung, and other solid tumors; and its lead product candidate, gedatolisib, a pan-PI3K/mTOR inhibitor in Phase 1b/2 trials for hormone receptor-positive, HER2-negative breast cancer in combination with palbociclib and fulvestrant, as well as for other solid tumors. The company operates in the United States, with headquarters in Minneapolis, Minnesota, where it was founded in 2012. Recent developments include positive interim data from the VIKTORIA-1 Phase 2 trial of gedatolisib in November 2024, demonstrating significant progression-free survival benefits; expansion of the CELsignia platform to additional cancer indications; and ongoing collaborations with academic institutions and pharmaceutical partners for companion diagnostic development.
Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
Celcuity Inc. (CELC) Discusses FDA Approval of REVTORPYK for Advanced HR+/HER2- Breast Cancer and Commercial Launch Plans Transcript
Celcuity: 'Buy' REVTORPYK FDA Approval First And sNDA Label Expansion Q3 2026
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
Celcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Celcuity: Selloff On Yesterday's Data Unwarranted - Buy Rating Upheld
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib Efficacy Transcript
What's Going On With Celcuity Stock On Tuesday?
Celcuity plunges after experimental breast cancer treatment data disappoints
Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026
Celcuity To Participate in Upcoming Investor Conferences
Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst